GERN - Recent Pullback Buying Opportunity For Blood Cancer Firm Geron: Goldman Sachs | Benzinga
Goldman Sachs has upgraded Geron Corporation (NASDAQ: GERN) to Buy from Neutral, with a price target of $4.
Recently, the FDA assigned a standard review and a Prescription Drug User Fee Act (PDUFA) action date of June 16, 2024, for Geron's New Drug Application (NDA) for imetelstat for transfusion-dependent anemia in patients with lower-risk myelodysplastic syndromes.
In addition, the FDA informed that it plans to hold an advisory committee meeting.
The analyst says that imetelstat will likely be approved in this setting, with unadjusted peak sales of $1.5 billion (probability of success of 90%).
Further, the recent approval of Bristol-Myers Squibb & Co (NYSE: